ZRANB3 and endometrial carcinoma: Other evidence links endometrial carcinoma (EC) to ZRANB3 loss-of-function, as several EC mutants in the ZRANB3 ATP-ase core and HNH domain showed both compromised ATP-ase and nuclease activities [27].